Healthcare / Drug Manufacturers - Specialty & GenericOTC Markets OTCPK
$15.64
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.2B · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$51.9B
P/E
43.4x
↑EV/EBITDA
1.1x
↓ROE
12.6%
↑Gross Margin
86.2%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.1%
FCF CAGR
—
FCF margin
26.2%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $31.63B · net income $7.71B · FCF $8.27B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $31.63B | $31.63B | $27.98B | $22.82B | $21.28B |
| Net Income | $7.71B | $7.71B | $6.34B | $4.30B | $3.91B |
| EBITDA | $9.57B | $9.57B | $7.95B | $5.38B | $4.55B |
| EPS | 2.36 | 2.36 | 2.00 | 1.36 | 1.22 |
| Gross Margin | 86.2% | 86.2% | 86.2% | 84.6% | 83.6% |
| Operating Margin | 27.2% | 27.2% | 24.3% | 20.3% | 15.7% |
| Net Margin | 24.4% | 24.4% | 22.6% | 18.9% | 18.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Current Ratio | 9.23 | 9.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $8.27B | $8.27B | $5.45B | $6.16B | $-726.9M |
| Returns | |||||
| ROE | 12.6% | 12.6% | 13.9% | 10.6% | 10.3% |
| Valuation | |||||
| P/E | 43.44 | 43.44 | — | — | — |
| EV/EBITDA | 1.07 | 1.07 | — | — | — |
| P/B | 0.83 | 0.83 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 13.0% | 13.0% | 22.6% | 7.3% | — |
| EPS Growth | 18.0% | 18.0% | 47.1% | 11.5% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-16.2%
EPS terminal req.
$1.39
Spread vs growth
34.2%
5Y implied EPS CAGR
-6.6%
EPS terminal req.
$1.68
Spread vs growth
24.6%
10Y implied EPS CAGR
1.4%
EPS terminal req.
$2.70
Spread vs growth
16.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.4%
Start / end P/E
8.6x → 6.6x
EPS bridge
2.00 → 2.36
Residual
-4.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.